<DOC>
	<DOCNO>NCT02503943</DOCNO>
	<brief_summary>Obesity one characteristic type 2 diabetes mellitus . Most obese diabetes patient combine dyslipidemia hypertension . The clustering diabetes , obesity , hypertension dyslipidemia increase risk cardiovascular event patient . GLP-1 ( glucagon like peptide-1 ) kind incretin discover recent year . It report beside hypoglycemic losing weight effect , activator GLP-1 receptor could decrease blood pressure improve lipid metabolism . Therefore , activation GLP-1 receptor may become new comprehensive treatment strategy improve glucose lipid metabolism , blood pressure level cardiovascular complication . But , lack evidence-based medicine proof relationship GLP-1 blood pressure serum lipid . So , investigator design prospective , randomize , open-label , active control study , try evaluate effect activator GLP-1 receptor ( liraglutide ) lower blood pressure , improve vascular function lipid metabolism overweight obese type 2 diabetic patient mask hypertension .</brief_summary>
	<brief_title>Effects Incretin Blood Pressure Lipid Patients With Overweight Obese Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Masked Hypertension</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>1 . Male female , age 3560 year old 2 . Type 2 diabetes 3 . 24kg/m²≤BMI≤32kg/m² , WC≥90cm male WC≥85cm female 4 . Grade 1 hypertension mask hypertension diagnose via 24h ambulatory blood pressure monitoring ( daytime blood pressure load 50 % ≥135/85 mmHg , night time blood pressure load 50 % ≥125/75 mmHg 24h blood pressure load 50 % ≥130/80 mmHg） 1 . Type 2 diabetes serious complication , diabetic neuropathy , diabetic retinopathy , stage IV diabetic nephropathy , acute diabetic complication . 2 . Type 1 diabetes . 3 . Diagnosed moderate severe sleep apnea syndrome ( SAS ) . 4 . Grade 2 Grade 3 hypertension . 5 . Triglyceride≥5.65mmol/L 6 . History cardiocerebral vascular event congestive heart failure , myocardial infarction stroke within 3 month . 7 . Hypohepatia ( AST AST twice high upper limit ) history hepatitis cirrhosis , hepatic encephalopathy . 8 . Renal insufficiency ( serum creatinine 1.5 time high upper limit ) history dialysis nephritic syndrome . 9 . Chronic obstructive pulmonary disease ( COPD ) , chronic respiratory failure hyoxemia . 10 . Acute infection , tumor , severe arrhythmia , mental disorder , alcohol medicine addiction . 11 . Fertile woman without contraceptive . 12 . Any surgical medical condition significantly influence absorption , distribution , metabolism excretion intervention drug . 13 . Allergic contraindication intervention drug .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Masked hypertension</keyword>
	<keyword>Lipid metabolism</keyword>
</DOC>